Non-Small Cell Lung Cancer clinical trials
Showing 301–350 of 711 active trials. Describe your situation to see which ones you may be eligible for.
- Phase 1 Study of PF-08046033 in Advanced Solid Tumors
- A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
- A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- Dabrafenib and/or Trametinib Rollover Study
- A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- Promoting Immunotherapy Efficacy With Low-Dose Liver RT
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
- First in Human Study of TORL-1-23 in Participants With Advanced Cancer
- Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors
- A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
- Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
- MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
- Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
- APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors
- Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
- Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
- M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
- JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
- Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
- First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
- Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
- A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
- A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
- Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- A Study of DS5361b in Participants With Advanced Solid Tumors
- A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
- Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
- A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
- A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
- A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Axelopran in Advanced Cancers
- Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color
- Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
- First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
- Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
- FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors
- Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
- A Study of PHN-012 in Patients With Advanced Solid Tumors
- A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
- Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
- A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors
- Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
- Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.